Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabio Cacciapaglia

Showing results (21-30 of 119) with videos related to

Pageof 12
Sort By:
Mediators of Inflammation|May 23, 2018
Atherosclerosis and AutoimmunityFrancesca Romana Spinelli, Francesca Barone, Fabio Cacciapaglia, et al.
Journal of Personalized Medicine|March 25, 2022
Comparison of Adalimumab to Other Targeted Therapies in Rheumatoid Arthritis: Results from Systematic Literature Review and Meta-AnalysisFabio Cacciapaglia, Vincenzo Venerito, Stefano Stano, et al.
Rheumatology (Oxford, England)|November 22, 2023
Effectiveness of biological targeted therapies may discriminate seronegative from seropositive rheumatoid arthritisFlorenzo Iannone, Giuseppe Lopalco, Fabio Cacciapaglia, et al.
Joint Bone Spine|September 26, 2024
Effectiveness of tapering rituximab dose in idiopathic inflammatory myopathies: Real-world data from a monocentric studyMarco Fornaro, Stefano Stano, Fabio Cacciapaglia, et al.
Rheumatology (Oxford, England)|October 26, 2019
Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritisFlorenzo Iannone, Mariangela Nivuori, Marco Fornaro, et al.
Rheumatology (Oxford, England)|October 11, 2019
Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosusMarco Fornaro, Laura Coladonato, Vincenzo Venerito, et al.
European Journal of Clinical Investigation|July 13, 2020
Cardiovascular risk estimation with 5 different algorithms before and after 5 years of bDMARD treatment in rheumatoid arthritisFabio Cacciapaglia, Marco Fornaro, Vincenzo Venerito, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|September 20, 2021
A Machine Learning Approach for Predicting Sustained Remission in Rheumatoid Arthritis Patients on Biologic AgentsVincenzo Venerito, Orazio Angelini, Marco Fornaro, et al.
Clinical and Experimental Rheumatology|July 12, 2021
Safety and effectiveness in switching from reference to biosimilar rituximab in rheumatoid arthritis patients: real world experience from a single Italian rheumatology centreFabio Cacciapaglia, Daniela Renna, Marco Fornaro, et al.
Rheumatology (Oxford, England)|November 26, 2019
Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosusMarco Fornaro, Laura Coladonato, Vincenzo Venerito, et al.
Pageof 12

Showing results (21-30 of 119) with videos related to

Sort By:
Pageof 12
Mediators of Inflammation|May 23, 2018
Atherosclerosis and AutoimmunityFrancesca Romana Spinelli, Francesca Barone, Fabio Cacciapaglia, et al.
Journal of Personalized Medicine|March 25, 2022
Comparison of Adalimumab to Other Targeted Therapies in Rheumatoid Arthritis: Results from Systematic Literature Review and Meta-AnalysisFabio Cacciapaglia, Vincenzo Venerito, Stefano Stano, et al.
Rheumatology (Oxford, England)|November 22, 2023
Effectiveness of biological targeted therapies may discriminate seronegative from seropositive rheumatoid arthritisFlorenzo Iannone, Giuseppe Lopalco, Fabio Cacciapaglia, et al.
Joint Bone Spine|September 26, 2024
Effectiveness of tapering rituximab dose in idiopathic inflammatory myopathies: Real-world data from a monocentric studyMarco Fornaro, Stefano Stano, Fabio Cacciapaglia, et al.
Rheumatology (Oxford, England)|October 26, 2019
Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritisFlorenzo Iannone, Mariangela Nivuori, Marco Fornaro, et al.
Rheumatology (Oxford, England)|October 11, 2019
Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosusMarco Fornaro, Laura Coladonato, Vincenzo Venerito, et al.
European Journal of Clinical Investigation|July 13, 2020
Cardiovascular risk estimation with 5 different algorithms before and after 5 years of bDMARD treatment in rheumatoid arthritisFabio Cacciapaglia, Marco Fornaro, Vincenzo Venerito, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|September 20, 2021
A Machine Learning Approach for Predicting Sustained Remission in Rheumatoid Arthritis Patients on Biologic AgentsVincenzo Venerito, Orazio Angelini, Marco Fornaro, et al.
Clinical and Experimental Rheumatology|July 12, 2021
Safety and effectiveness in switching from reference to biosimilar rituximab in rheumatoid arthritis patients: real world experience from a single Italian rheumatology centreFabio Cacciapaglia, Daniela Renna, Marco Fornaro, et al.
Rheumatology (Oxford, England)|November 26, 2019
Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosusMarco Fornaro, Laura Coladonato, Vincenzo Venerito, et al.
Pageof 12